Markets

Metagenomi Therapeutics To Present Presentation On Preclinical Data Of MGX-001 At 68th American Society Of Hematology Annual Meeting

Nov 4, 2026 · 09:29 AM ET· updated 54m ago

Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that

Why It Matters

Metagenomi will show early lab results for a new genetic medicine. This is a chance to learn if their treatment idea could work for blood diseases.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MGX0.78

+0.02 (+2.68%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.